IDL Diagnostics AB (publ) invites investors, media and the public to virtually attend a Live Strategy Update on the 27th of November 2025 at 09:00 at Redeye (www.redeye.se).
CEO Anders Hultman and members of the management team will inform about recent progress and key strategic activities and opportunities for 2026 and beyond.
Following the presentation there will be a Q&A session moderated by Redeye analyst Oscar Bergman.
Viewers will have the opportunity to ask questions through the webcast video chat.
Contacts
Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com
About IDL Diagnostics
IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.idldiagnostics.com
Attachments
IDL Diagnostics will have a Strategy Update on the 27th of November
© Modular Finance, source Nordic Press Releases